Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
Top Page
Evolus
(NASDAQ:EOLS)
54Neutral
Positive Factors
Financial Outlook
The stock is seen as undervalued, with analysts believing the recent sell-off is overdone, suggesting potential for a rebound.
Market Share
Evolus is positioned to gain market share with its growing aesthetics franchise.
Product Launch
Evolus is evolving into a multi-product company with the upcoming U.S. launch of Evolysse, which is anticipated to have a successful launch given synergies with Evolus' commercial infrastructure.
Negative Factors
Consumer Spending
Risks to the rating and price target include a deteriorating consumer spending environment, competition, pricing pressure, a slower ramp of Evolysse, supply chain challenges, potential tariffs, regulatory delays, higher-than-expected operating expenses, and negative clinical data updates.
Economic Sensitivity
The dermal filler market is more economically sensitive given the higher price point.
Evolus (EOLS) vs. S&P 500 (SPY)
Market Cap
$748.50M
Dividend YieldN/A
Average Volume (3M)924.75K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth31.76%
EPS Growth24.85%
CountryUS
Employees332
SectorHealthcare
Sector Strength53
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.15
Shares Outstanding64,470,590
10 Day Avg. Volume764,189
30 Day Avg. Volume924,746
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.12
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$24.29Price Target Upside106.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Evolus Business Overview & Revenue Model
Company DescriptionEvolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
How the Company Makes MoneyEvolus generates revenue primarily through the sale of its aesthetic product, Jeuveau®. The company targets its sales efforts towards dermatologists, plastic surgeons, and aesthetic practitioners, leveraging a specialized sales force to promote its product. Jeuveau® is distributed through a network of third-party distributors and direct sales channels. A significant portion of Evolus's revenue is derived from the U.S. market, although the company is also expanding its presence internationally. In addition to direct sales, Evolus engages in strategic partnerships and distribution agreements to enhance market penetration and broaden its customer base. The company focuses heavily on branding and marketing initiatives to increase product awareness and drive demand, which are critical factors in its revenue generation strategy.
Evolus Financial Statement Overview
Summary
Evolus is showing revenue growth and improved gross profit margins, but it remains unprofitable with ongoing net losses. The balance sheet has low equity levels, and cash flow from operations is negative, though improving. The company needs to focus on profitability and strengthening its balance sheet for better financial stability.Income Statement
Evolus has demonstrated consistent revenue growth over the years, increasing from $34.9 million in 2019 to $264.3 million in 2024. However, the company is still facing profitability challenges, with negative net income each year. The gross profit margin has improved significantly, reflecting better cost management. Despite this, negative EBIT and EBITDA margins indicate ongoing operational losses.―
Balance Sheet
Evolus's balance sheet shows a concerning debt-to-equity ratio due to low equity levels, which have been negative in several years. The company’s total debt has decreased, but stockholders' equity remains minimal, affecting overall financial stability. Positive cash balances partially mitigate these risks, but improvements in equity are needed for stronger financial health.45
Cash Flow
Cash flow from operations remains negative, but there has been a decrease in the deficit over time, indicating potential improvements. Free cash flow is also negative, reflecting continued cash burn. However, the company has been able to secure financing to bolster cash reserves, which is crucial for operations in the short term.―
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 264.31M | 202.09M | 148.62M | 99.67M | 56.54M | Gross Profit |
| 180.34M | 140.53M | 92.73M | 56.14M | 38.24M | EBIT |
| -34.41M | -49.23M | -57.58M | -63.62M | -68.70M | EBITDA |
| -25.00M | -41.81M | -60.72M | -39.06M | -144.75M | Net Income Common Stockholders |
| -50.42M | -61.69M | -74.41M | -46.81M | -163.01M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 86.95M | 62.84M | 53.92M | 146.26M | 107.56M | Total Assets |
| 232.57M | 189.00M | 177.98M | 257.48M | 209.07M | Total Debt |
| 8.47M | 126.55M | 73.20M | 74.74M | 138.32M | Net Debt |
| -78.48M | 63.71M | 19.28M | -71.51M | 35.76M | Total Liabilities |
| 227.05M | 209.69M | 159.48M | 175.61M | 282.03M | Stockholders Equity |
| 5.52M | -20.69M | 18.50M | -422.88M | -376.07M |
| Cash Flow | Free Cash Flow | |||
| -19.47M | -35.63M | -11.71M | -34.36M | -61.01M | Operating Cash Flow |
| -18.00M | -34.01M | -8.77M | -33.39M | -57.87M | Investing Cash Flow |
| -4.82M | -1.63M | -1.39M | 4.03M | 12.19M | Financing Cash Flow |
| 47.41M | 44.64M | -1.52M | 73.05M | 38.35M |
Evolus Technical Analysis
Neutral
11.76
Price Trends
12.08
Negative
12.27
Negative
13.52
Negative
Market Momentum
0.04
Negative
53.06
Neutral
66.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOLS, the sentiment is Neutral. The current price of 11.76 is above the 20-day moving average (MA) of 10.98, below the 50-day MA of 12.08, and below the 200-day MA of 13.52, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 53.06 is Neutral, neither overbought nor oversold. The STOCH value of 66.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EOLS.
Evolus Risk Analysis
Evolus disclosed 52 risk factors in its most recent earnings report. Evolus reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evolus Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $376.49M | 6.36 | 28.70% | 10.13% | -0.86% | -13.33% | |
70 Outperform | $888.44M | 15.03 | 32.62% | ― | 11.41% | 45.89% | |
59 Neutral | $659.64M | 928.57 | 0.26% | ― | 11.29% | -79.52% | |
56 Neutral | $834.88M | ― | -34.65% | ― | 252.64% | 85.10% | |
54 Neutral | $748.50M | ― | -913.07% | ― | 31.76% | 24.85% | |
52 Neutral | $5.23B | 3.70 | -41.86% | 2.84% | 16.58% | -0.16% | |
44 Neutral | $424.87M | ― | -31.06% | ― | 11.22% | -108.58% |
* Healthcare Sector Average
Performance Comparison
EOLS
Evolus
11.76
-1.37
-10.43%
AVDL
Avadel Pharmaceuticals
9.47
-6.36
-40.18%
SIGA
SIGA Technologies
5.25
-1.77
-25.21%
COLL
Collegium Pharmaceutical
27.05
-10.81
-28.55%
ORGO
Organogenesis Holdings
5.18
2.90
127.19%
TLRY
Tilray
0.43
-1.55
-78.28%
Evolus Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q1-2025)
| % Change Since: 0.00%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Positive
Evolus reported strong revenue growth and a successful product launch, with significant customer engagement and financial repositioning. However, challenges include reduced market growth expectations, tariff impacts, and increased operating expenses. Despite these challenges, the company's strategic execution and market share gains indicate a positive outlook.Q1-2025 Updates
Positive Updates
Double-Digit Revenue Growth
Evolus reported a 15.5% revenue growth in the first quarter of 2025, achieving $68.5 million in revenue, supported by a strong commercial engine and market share gains.
Successful Launch of Evolysse
Evolus launched its new product, Evolysse, in April 2025, which has shown strong early momentum and exceeded expectations in terms of clinician interest and early ordering activity.
Increased Customer Engagement
Evolus added 675 new purchasing accounts, reaching a total of more than 16,000 accounts. The company's loyalty program achieved a record with over 220,000 redemptions.
Positive Financial Repositioning
Evolus successfully refinanced its debt facility, reducing borrowing costs by 350 basis points and adding $100 million in incremental available capacity.
International Growth
International revenue contributions increased and are expected to continue outpacing US growth, validating strong growth trajectory outside the US.
Negative Updates
Reduced Market Growth Expectations
Evolus reduced its 2025 toxin market growth expectation to low single digits due to slower market growth and a cautious market environment.
Impact of Tariffs
Evolysse is subject to a 10% tariff, expected to increase to 20%, impacting cost of goods sold. The estimated tariff impact is less than $2 million for 2025.
Increased Operating Expenses
GAAP operating expenses for the first quarter increased to $61.8 million, up from $54.9 million in the previous quarter, reflecting investments in growth and commercial expansion.
Company Guidance
In the first quarter of 2025, Evolus reported $68.5 million in revenue, marking a 15.5% increase from the previous year, as they gained market share despite a slower overall market growth. The company launched Evolysse Form and Evolysse Smooth in the U.S., transitioning to a multi-product company and driving engagement with their "Drop the F Word" campaign, which encourages a shift in terminology from "filler" to "hyaluronic acid." Evolus reaffirmed their 2025 revenue guidance of $345 million to $355 million, predicting over 30% annual growth. They noted a strong customer base with 675 new accounts added, and over 220,000 loyalty program redemptions, 65% from existing consumers. The company's non-GAAP operating expenses were between $230 million and $240 million, and Evolus is on track to achieve profitability by the end of 2025.Evolus Corporate Events
Private Placements and FinancingBusiness Operations and Strategy
Evolus Secures New $250 Million Credit Facility
Positive
May 5, 2025
On May 5, 2025, Evolus, Inc. announced an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million facility managed by Pharmakon Advisors, LP. This refinancing reduces the company’s interest expenses, enhances financial flexibility, and provides additional capital availability. The new agreement includes a lower interest rate and a conversion to a bullet maturity payment structure, eliminating pre-payment fees from the existing facility. This strategic move is expected to improve Evolus’ cash generation and support its commercial momentum and strategic initiatives.
Spark’s Take on EOLS Stock
According to Spark, TipRanks’ AI Analyst, EOLS is a Neutral.
Evolus’s overall score reflects its strong revenue growth and profitability ahead of schedule, which are significant positives. However, ongoing unprofitability, weak technical indicators, and unattractive valuation weigh down the score. Improving financial stability and managing market challenges are critical for enhancing investor confidence.
To see Spark’s full report on EOLS stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.